Alternative Splice Variant-Derived Neoantigen-Targeted Immunotherapy in Diffuse Hemispheric Glioma, H3 G34-Mutant
Abstract
This proposal seeks to develop a new mode of immunotherapy targeting a rare brain tumor type that afflicts children and young adults. We utilize techniques (long-read RNA-seq) to develop a new, more robust computational method (IRIS2) to identify targets for immunotherapy that are unique to this tumor type (diffuse hemispheric glioma, H3 G34-mutant). This tumor is a particularly ideal candidate for such an approach in that the mechanisms by which this tumor develops involves RNA dysregulation, which IRIS2 is made to explore. We have shown that designing immunotherapy against targets identified by an earlier version of IRIS can direct the immune system to effectively identify and kill this particular type of tumor with striking efficacy. We propose to expand upon these early studies to develop immunotherapy against this and other cancer types. The potential impact of our success will be relevant to active-duty Service Members, Veterans, and the family of Service Members, including their children, by studying a cancer that kills young, healthy boys and girls, with an eye toward developing a clinical trial to offer a better treatment. Moreover, the relevant findings will provide a basis upon which to explore similar strategies in other brain tumor types.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252310616
Entities
People
- Anthony Wang
Organizations
- United States Army
- University of California, Los Angeles